Literature DB >> 7472929

Favorable outcome in children with Beckwith-Wiedemann syndrome and intraabdominal malignant tumors.

W G Vaughan1, D W Sanders, J L Grosfeld, D A Plumley, F J Rescorla, L R Scherer, K W West, P P Breitfeld.   

Abstract

Children with Beckwith-Wiedemann syndrome (BWS) have an increased risk of developing Wilms' tumors, hepatoblastomas, and adrenal tumors. This study evaluates disease-free survival in children with BWS and intraabdominal tumors. Sixteen tumors occurred in 13 children with BWS (8 boys, 5 girls). Diagnoses included Wilms' tumor (10) (2 bilateral, 20%), hepatoblastoma (2), bladder rhabdomyosarcoma (1), and adrenal cortical tumor (1). In the 10 children with Wilms' tumor, the average age at diagnosis was 3.5 years (range, 7 months to 5 years). Nine of 10 had initial tumor resection, chemotherapy, and radiation therapy (when indicated). One child with bilateral disease had tumor biopsy, chemotherapy, and partial nephrectomy. Tumors were classified as stage I (5), stage II (2), stage IV (1) and stage V (2), all with favorable histology. Disease-free survival rate was 100% with median follow-up of 9 years (range, 4 to 22 years). One patient had a left adrenal tumor detected during screening sonography 11 years after Wilms' tumor resection. Two infants with advanced-stage hepatoblastoma responded to chemotherapy, allowing subsequent complete hepatic resection. Both tumors had unfavorable histology. Both completed postoperative chemotherapy and have no evidence of disease (NED) with normal alpha-fetoprotein levels at 21 and 12 months, respectively, after tumor detection. One patient with stage III (group 3) bladder rhabdomyosarcoma underwent partial cystectomy following chemoradiation and is alive (NED) after 20 months. Children with BWS should be screened at regular intervals (every 3 to 6 months) for renal, adrenal, and hepatic tumors. The exact duration of screening is not yet determined.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7472929     DOI: 10.1016/0022-3468(95)90338-0

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  8 in total

Review 1.  [Current status of diagnosis and treatment of hepatoblastoma].

Authors:  Purificación García-Miguel; Manuel López Santamaría
Journal:  Clin Transl Oncol       Date:  2005-08       Impact factor: 3.405

2.  Metachronous bilateral soft tissue sarcoma of the extremities.

Authors:  A Daigeler; M Lehnhardt; A Sebastian; O Belyaev; L Steinstraesser; H U Steinau; C Kuhnen
Journal:  Langenbecks Arch Surg       Date:  2007-01-23       Impact factor: 3.445

3.  The effectiveness of Wilms tumor screening in Beckwith-Wiedemann spectrum.

Authors:  Alessandro Mussa; Kelly A Duffy; Diana Carli; Jessica R Griff; Riccardo Fagiano; Jonida Kupa; Garrett M Brodeur; Giovanni Battista Ferrero; Jennifer M Kalish
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-04       Impact factor: 4.553

4.  Hepatoblastoma: Analysis of treatment outcome from a tertiary care center.

Authors:  Sanju Cyriac; Ramakrishnan Ayloor Seshadri; Arun Warrier; Tenali Gnana Sagar
Journal:  J Indian Assoc Pediatr Surg       Date:  2011-01

5.  Detection of Serum Protein Biomarkers for the Diagnosis and Staging of Hepatoblastoma.

Authors:  Wei Zhao; Juan Li; Junjie Zhang; Pengfei Gao; Hang Pei; Lei Wang; Fei Guo; Jiekai Yu; Shu Zheng; Jiaxiang Wang
Journal:  Int J Mol Sci       Date:  2015-06-04       Impact factor: 5.923

6.  GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3.

Authors:  Yihua Pei; Qin Yao; Sibo Yuan; Bozhen Xie; Yan Liu; Chunsheng Ye; Huiqin Zhuo
Journal:  Oncotarget       Date:  2016-11-22

7.  Circulating D-dimer level correlates with disease characteristics in hepatoblastoma patients.

Authors:  BinBin Zhang; GongBao Liu; XiangQi Liu; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

Review 8.  Pediatric Rhabdomyosarcoma: Epidemiology and Genetic Susceptibility.

Authors:  Bailey A Martin-Giacalone; P Adam Weinstein; Sharon E Plon; Philip J Lupo
Journal:  J Clin Med       Date:  2021-05-09       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.